Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 16;11:1789–1802. doi: 10.2147/DDDT.S138320

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Gao et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

The effect of morusin on protein expressions of the IL-6/STAT3 signaling pathway.

Notes: HepG2 cells (A) or Hep3B cells (B) were treated with the indicated concentrations of morusin for 48 h and analyzed for p-STAT3 (Tyr705), p-STAT3 (Ser727), and STAT3 levels using Western blot analysis. (C) The histograms show that there was a significant decrease in p-STAT3 (Tyr705) and p-STAT3 (Ser727) but not in the total STAT3 expression after morusin treatment. (D, E) HCC cells were treated with the indicated concentrations of morusin for 24 h and were then induced by IL-6 for 15 min, after which whole-cell extracts were processed for Western blot analysis. (F) The histograms show that there was a decrease in p-STAT3 (Tyr705) and p-STAT3 (Ser727) but not in the total STAT3 expression after morusin treatment. (G) Western blot analysis of protein expressions in the IL-6/STAT3 signaling pathway in morusin-treated tumor tissues. (H) The histogram shows that expression levels of IL-6, p-STAT3 (Tyr705), and p-STAT3 (Ser727) decreased. *P<0.05, **P<0.01. Three parallel experiments were performed.

Abbreviation: HCC, hepatocellular carcinoma.

The effect of morusin on protein expressions of the IL-6/STAT3 signaling pathway.

Notes: HepG2 cells (A) or Hep3B cells (B) were treated with the indicated concentrations of morusin for 48 h and analyzed for p-STAT3 (Tyr705), p-STAT3 (Ser727), and STAT3 levels using Western blot analysis. (C) The histograms show that there was a significant decrease in p-STAT3 (Tyr705) and p-STAT3 (Ser727) but not in the total STAT3 expression after morusin treatment. (D, E) HCC cells were treated with the indicated concentrations of morusin for 24 h and were then induced by IL-6 for 15 min, after which whole-cell extracts were processed for Western blot analysis. (F) The histograms show that there was a decrease in p-STAT3 (Tyr705) and p-STAT3 (Ser727) but not in the total STAT3 expression after morusin treatment. (G) Western blot analysis of protein expressions in the IL-6/STAT3 signaling pathway in morusin-treated tumor tissues. (H) The histogram shows that expression levels of IL-6, p-STAT3 (Tyr705), and p-STAT3 (Ser727) decreased. *P<0.05, **P<0.01. Three parallel experiments were performed.

Abbreviation: HCC, hepatocellular carcinoma.